Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 11/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2687414 | 0.90 | KCNH2 (0.64) | KCNH2CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL4136600 | 0.89 | KCNH2 (0.63) | KCNH2CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL2685770 | 0.89 | KCNH2 (0.63) | KCNH2CYP3A4CYP2D6 | |
| SCHEMBL4303205 | 0.86 | KCNH2 (0.49) | KCNH2CYP3A4CYP2D6 | |
| SCHEMBL12090741 | 0.85 | KCNH2 (0.52) | KCNH2CYP3A4CYP2D6 | |
| SCHEMBL707415 | 0.85 | KCNH2 (0.61) | KCNH2 | |
| Hydrochloric Acid SCHEMBL2798199 | 0.84 | KCNH2 (0.60) | KCNH2 | |
| SCHEMBL19094022 | 0.83 | KCNH2 (0.49) | KCNH2CYP3A4CYP2D6 | |
| SCHEMBL11999992 | 0.82 | KCNH2 (0.48) | KCNH2CYP3A4CYP2D6 | |
| SCHEMBL2685561 | 0.82 | KCNH2 (0.61) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2379554-B1 | NAPHTHYRIDIN-2(1H)-ONE COMPOUNDS USEFUL AS ANTIBACTERIALS | GLAXO GROUP LTD (GB) | 2015-11-11 | — | — | EP | disclosed |
| EP-2379554-B1 | NAPHTHYRIDIN-2(1H)-ONE COMPOUNDS USEFUL AS ANTIBACTERIALS | GLAXO GROUP LTD (GB) | 2015-11-11 | — | — | EP | disclosed |
| US-8318940-B2 | Naphthyridin-2 (1 H)-one compounds useful as antibacterials | GLAXO GROUP LIMITED (GB) | 2012-11-27 | — | — | US | disclosed |
| US-8318940-B2 | Naphthyridin-2 (1 H)-one compounds useful as antibacterials | GLAXO GROUP LIMITED (GB) | 2012-11-27 | — | — | US | disclosed |
| US-8318940-B2 | Naphthyridin-2 (1 H)-one compounds useful as antibacterials | GLAXO GROUP LIMITED (GB) | 2012-11-27 | — | — | US | disclosed |
| US-20120115899-A1 | NAPHTHYRIDIN-2 (1 H)-ONE COMPOUNDS USEFUL AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2012-05-10 | — | — | US | disclosed |
| US-20120115899-A1 | NAPHTHYRIDIN-2 (1 H)-ONE COMPOUNDS USEFUL AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2012-05-10 | — | — | US | disclosed |
| US-20120115899-A1 | NAPHTHYRIDIN-2 (1 H)-ONE COMPOUNDS USEFUL AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2012-05-10 | — | — | US | disclosed |
| US-20110319424-A1 | NAPHTHYRIDIN-2(1H) -ONE COMPOUNDS USEFUL AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2011-12-29 | — | — | US | disclosed |
| US-20110319424-A1 | NAPHTHYRIDIN-2(1H) -ONE COMPOUNDS USEFUL AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2011-12-29 | — | — | US | disclosed |
| US-20110319424-A1 | NAPHTHYRIDIN-2(1H) -ONE COMPOUNDS USEFUL AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2011-12-29 | — | — | US | disclosed |
| WO-2010081874-A1 | NAPHTHYRIDIN-2 (1 H)-ONE COMPOUNDS USEFUL AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2010-07-22 | — | — | WO | disclosed |
| WO-2009090222-A1 | NAPHTHYRIDIN-2(1H) -ONE COMPOUNDS USEFUL AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2009-07-23 | — | — | WO | disclosed |
| EP-2080761-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2009-07-22 | — | — | EP | disclosed |
| EP-2080761-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2009-07-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319424-A1 | NAPHTHYRIDIN-2(1H) -ONE COMPOUNDS USEFUL AS ANTIBACTERIALS | RIF1, MRPL21, NAT1 | KCNH2 3252/4885CYP3A4 912/4885CYP2D6 438/4885 |
| US-20120115899-A1 | NAPHTHYRIDIN-2 (1 H)-ONE COMPOUNDS USEFUL AS ANTIBACTERIALS | NAT1, RIF1, MRPL21 | KCNH2 2185/4885CYP3A4 848/4885CYP2D6 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.